PAR paradigm biopharmaceuticals limited..

Funding options, page-14

  1. 9,224 Posts.
    lightbulb Created with Sketch. 7958
    Seemed most relevant here...don't shoot the messenger.

    An insider, the founder of SurgCenter, essentially a vast day hospital network in the US, has just bought 10,000,000 shares in MSB.

    Now I apologise to those who hate MSB discussions to PAR, but there is relevance.

    SurgCenter is a massive ambulatory network with orthopedic specialisation; "performed over 4100 Total Joint Replacements, more than any other outpatient surgery center in the United States". If they are looking at MSB, there is no way they, and others, will be unaware of PAR's Zilosul injectable Pentosan Polysulfate Sodium (iPPS) treatment of symptomatic osteoarthritis, the bread and butter of its patients presentations.

    A massive outpatient network that could so easily apply an injectable in its business. WIth PAR's NFL affiliations, there is no way SurgCenter and others are unaware of PAR. WHilst many PAR owners will probably dislike the cross discussion, its relevant. If US big Pharma is buying into MSB, its not going to be unaware of PAR.....

    A potential source of funding, or even predatory take over at these cheap prices....
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
42.0¢
Change
-0.020(4.55%)
Mkt cap ! $166.9M
Open High Low Value Volume
44.5¢ 44.5¢ 41.5¢ $271.6K 637.8K

Buyers (Bids)

No. Vol. Price($)
2 5960 42.0¢
 

Sellers (Offers)

Price($) Vol. No.
43.0¢ 3696 1
View Market Depth
Last trade - 16.10pm 16/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.